{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:12:47Z","timestamp":1793761967272,"version":"4.6.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03309-1","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T18:51:18Z","timestamp":1753469478000},"page":"4270-4299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10\u00a0Years Post-Approval"],"prefix":"10.1007","volume":"42","author":[{"given":"Aliya A.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wakeford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"1","key":"3309_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","volume":"20","author":"W H\u00f6gler","year":"2019","unstructured":"H\u00f6gler W, Langman C, da Silva HG, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20(1):80. https:\/\/doi.org\/10.1186\/s12891-019-2420-8.","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"3309_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","volume":"14","author":"F Conti","year":"2017","unstructured":"Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017;14(2):230\u20134. https:\/\/doi.org\/10.11138\/ccmbm\/2017.14.1.230.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"3309_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","volume":"65","author":"TJ Weber","year":"2016","unstructured":"Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65:1522\u201330. https:\/\/doi.org\/10.1016\/j.metabol.2016.07.006.","journal-title":"Metabolism"},{"issue":"6","key":"3309_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/archpedi.1948.02030020840003","volume":"75","author":"JC Rathbun","year":"1948","unstructured":"Rathbun JC. Hypophosphatasia; a new developmental anomaly. Am J Dis Child. 1948;75(6):822\u201331. https:\/\/doi.org\/10.1001\/archpedi.1948.02030020840003.","journal-title":"Am J Dis Child"},{"issue":"1","key":"3309_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.2015-3462","volume":"101","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334\u201342. https:\/\/doi.org\/10.1210\/jc.2015-3462.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3309_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"1366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia [with Supplementary Appendix]. N Engl J Med. 2012;1366(10):904\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1106173.","journal-title":"N Engl J Med"},{"key":"3309_CR7","volume-title":"Strensiq [package insert]","author":"A Pharmaceuticals","year":"2024","unstructured":"Alexion Pharmaceuticals. Strensiq [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc; 2024."},{"key":"3309_CR8","unstructured":"Alexion Europe SAS. Strensiq [summary of product characteristics]. Levollois-Perret, France: Alexion Europe, 2020."},{"key":"3309_CR9","unstructured":"Report on the Deliberation Results: Strensiq Subcutaneous Injection. Pharmaceuticals and Medical Devices Agency, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare 2015. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0001.html#select19. Accessed May 6, 2025."},{"key":"3309_CR10","unstructured":"Alexion Pharmaceuticals. Strensiq (asfotase alfa) receives marketing approval in Japan for treatment of patients with hypophosphatasia (HPP) [press release]. Alexion Pharmaceuticals, 2015. https:\/\/www.fiercepharma.com\/pharma-asia\/strensiq%C2%AE-asfotase-alfa-receives-marketing-approval-japan-for-treatment-of-patients. Accessed May 6, 2025."},{"issue":"1\u20132","key":"3309_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","volume":"122","author":"PS Kishnani","year":"2017","unstructured":"Kishnani PS, Rush ET, Arundel P, et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017;122(1\u20132):4\u201317. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.010.","journal-title":"Mol Genet Metab"},{"key":"3309_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2019.01.049","volume":"209","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Leung E, Wilcox WR, et al. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr. 2019;209:116\u201324. https:\/\/doi.org\/10.1016\/j.jpeds.2019.01.049.","journal-title":"J Pediatr"},{"issue":"5","key":"3309_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/ec-22-0240","volume":"12","author":"W H\u00f6gler","year":"2023","unstructured":"H\u00f6gler W, Linglart A, Petryk A, et al. Growth and disease burden in children with hypophosphatasia. Endocr Connect. 2023;12(5): e220240. https:\/\/doi.org\/10.1530\/ec-22-0240.","journal-title":"Endocr Connect"},{"issue":"3","key":"3309_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000531865","volume":"97","author":"G Martos-Moreno","year":"2024","unstructured":"Martos-Moreno G, Rockman-Greenberg C, Ozono K, et al. Clinical profiles of children with hypophosphatasia prior to treatment with enzyme replacement therapy: an observational analysis from the Global HPP Registry. Horm Res Paediatr. 2024;97(3):233\u201342. https:\/\/doi.org\/10.1159\/000531865.","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"3309_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","volume":"17","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, Seefried L, Kishnani PS, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17(1):277. https:\/\/doi.org\/10.1186\/s13023-022-02393-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3309_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00198-018-4552-3","volume":"29","author":"F Genest","year":"2018","unstructured":"Genest F, Seefried L. Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all. Osteoporos Int. 2018;29(8):1815\u201325. https:\/\/doi.org\/10.1007\/s00198-018-4552-3.","journal-title":"Osteoporos Int"},{"issue":"4","key":"3309_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/BOR.0000000000000286","volume":"28","author":"K Briot","year":"2016","unstructured":"Briot K, Roux C. Adult hypophosphatasia. Curr Opin Rheumatol. 2016;28(4):448\u201351. https:\/\/doi.org\/10.1097\/BOR.0000000000000286.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3309_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","volume":"35","author":"A Khan","year":"2024","unstructured":"Khan A, Brandi ML, Rush ET, et al. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024;35(3):431\u20138. https:\/\/doi.org\/10.1007\/s00198-023-06844-1.","journal-title":"Osteoporos Int"},{"issue":"1","key":"3309_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33176\/aacb-19-00031","volume":"41","author":"JP Salles","year":"2020","unstructured":"Salles JP. Hypophosphatasia: biological and clinical aspects, avenues for therapy. Clin Biochem Rev. 2020;41(1):13\u201327. https:\/\/doi.org\/10.33176\/aacb-19-00031.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"3309_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2021.03.011","volume":"133","author":"PS Kishnani","year":"2021","unstructured":"Kishnani PS, Del Angel G, Zhou S, Rush ET. Investigation of ALPL variant states and clinical outcomes: an analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2021;133(1):113\u201321. https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.011.","journal-title":"Mol Genet Metab"},{"key":"3309_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-94-017-7197-9_2","volume":"76","author":"E Mornet","year":"2015","unstructured":"Mornet E. Molecular genetics of hypophosphatasia and phenotype-genotype correlations. Subcell Biochem. 2015;76:25\u201343. https:\/\/doi.org\/10.1007\/978-94-017-7197-9_2.","journal-title":"Subcell Biochem"},{"key":"3309_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","volume":"75","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, Zhang F, Wenkert D, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone. 2015;75:229\u201339. https:\/\/doi.org\/10.1016\/j.bone.2015.02.022.","journal-title":"Bone"},{"issue":"3","key":"3309_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-020-00771-7","volume":"108","author":"NM Jandl","year":"2021","unstructured":"Jandl NM, Schmidt T, Rolvien T, et al. Genotype-phenotype associations in 72 adults with suspected ALPL-associated hypophosphatasia. Calcif Tissue Int. 2021;108(3):288\u2013301. https:\/\/doi.org\/10.1007\/s00223-020-00771-7.","journal-title":"Calcif Tissue Int"},{"key":"3309_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116947","volume":"178","author":"MR Farman","year":"2024","unstructured":"Farman MR, Rehder C, Malli T, et al. The Global ALPL Gene Variant Classification Project: dedicated to deciphering variants. Bone. 2024;178: 116947. https:\/\/doi.org\/10.1016\/j.bone.2023.116947.","journal-title":"Bone"},{"key":"3309_CR25","doi-asserted-by":"publisher","first-page":"1138599","DOI":"10.3389\/fendo.2023.1138599","volume":"14","author":"KM Dahir","year":"2023","unstructured":"Dahir KM, Kishnani PS, Martos-Moreno GA, et al. Impact of muscular symptoms and\/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: a cross-sectional analysis from the Global HPP Registry. Front Endocrinol. 2023;14:1138599. https:\/\/doi.org\/10.3389\/fendo.2023.1138599.","journal-title":"Front Endocrinol"},{"issue":"4","key":"3309_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jmg-2024-110383","volume":"62","author":"PS Kishnani","year":"2025","unstructured":"Kishnani PS, Seefried L, Dahir KM, et al. Disease burden by ALPL variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry. J Med Genet. 2025;62(4):249\u201357. https:\/\/doi.org\/10.1136\/jmg-2024-110383.","journal-title":"J Med Genet"},{"issue":"Suppl 2","key":"3309_CR27","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"key":"3309_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325. https:\/\/doi.org\/10.1016\/j.bone.2017.02.011.","journal-title":"Bone"},{"issue":"12","key":"3309_CR29","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Rak D, Petryk A, Genest F. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. Osteoporos Int. 2021;32(12):2505\u201313. https:\/\/doi.org\/10.1007\/s00198-021-06025-y.","journal-title":"Osteoporos Int"},{"issue":"26","key":"3309_CR30","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1056\/NEJMra1511117","volume":"374","author":"AK Rosenthal","year":"2016","unstructured":"Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575\u201384. https:\/\/doi.org\/10.1056\/NEJMra1511117.","journal-title":"N Engl J Med"},{"issue":"4","key":"3309_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia\u2014aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233\u201346. https:\/\/doi.org\/10.1038\/nrendo.2016.14.","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl 1","key":"3309_CR32","first-page":"602","volume":"36","author":"D Devore","year":"2024","unstructured":"Devore D, Ruanova J, Dunn D, et al. Efzimfotase alfa improves skeletal muscle spare respiratory capacity in a mouse model of hypophosphatasia [abstract P1335]. Aging Clin Exp Res. 2024;36(Suppl 1):602.","journal-title":"Aging Clin Exp Res"},{"key":"3309_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116504","volume":"163","author":"Z Shajani-Yi","year":"2022","unstructured":"Shajani-Yi Z, Ayala-Lopez N, Black M, Dahir KM. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults. Bone. 2022;163: 116504. https:\/\/doi.org\/10.1016\/j.bone.2022.116504.","journal-title":"Bone"},{"issue":"3","key":"3309_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/(sici)1097-0177(199703)208:3<432::aid-aja13>3.0.co;2-1","volume":"208","author":"S Narisawa","year":"1997","unstructured":"Narisawa S, Fr\u00f6hlander N, Mill\u00e1n JL. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev Dyn. 1997;208(3):432\u201346. https:\/\/doi.org\/10.1002\/(sici)1097-0177(199703)208:3%3c432::aid-aja13%3e3.0.co;2-1.","journal-title":"Dev Dyn"},{"issue":"6","key":"3309_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1359\/jbmr.071213","volume":"23","author":"JL Millan","year":"2008","unstructured":"Millan JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008;23(6):777\u201387. https:\/\/doi.org\/10.1359\/jbmr.071213.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"3309_CR36","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/jbmr.1619","volume":"27","author":"MC Yadav","year":"2012","unstructured":"Yadav MC, de Oliveira RC, Foster BL, et al. Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res. 2012;27(8):1722\u201334. https:\/\/doi.org\/10.1002\/jbmr.1619.","journal-title":"J Bone Miner Res"},{"key":"3309_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bone.2015.05.005","volume":"78","author":"J Liu","year":"2015","unstructured":"Liu J, Campbell C, Nam HK, et al. Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia. Bone. 2015;78:203\u201311. https:\/\/doi.org\/10.1016\/j.bone.2015.05.005.","journal-title":"Bone"},{"issue":"4","key":"3309_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0022034510393517","volume":"90","author":"MD McKee","year":"2011","unstructured":"McKee MD, Nakano Y, Masica DL, et al. Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia. J Dent Res. 2011;90(4):470\u20136. https:\/\/doi.org\/10.1177\/0022034510393517.","journal-title":"J Dent Res"},{"issue":"7","key":"3309_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104787","volume":"66","author":"K Yoshida","year":"2023","unstructured":"Yoshida K, Ishizuka S, Nakamura-Takahashi A, et al. Prenatal asfotase alfa-mediated enzyme replacement therapy restores delayed calcification in a severe infantile form of hypophosphatasia model mice. Eur J Med Genet. 2023;66(7): 104787. https:\/\/doi.org\/10.1016\/j.ejmg.2023.104787.","journal-title":"Eur J Med Genet"},{"key":"3309_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.reth.2021.06.002","volume":"18","author":"A Hasegawa","year":"2021","unstructured":"Hasegawa A, Nakamura-Takahashi A, Kasahara M, et al. Prenatal enzyme replacement therapy for Akp2 (-\/-) mice with lethal hypophosphatasia. Regen Ther. 2021;18:168\u201375. https:\/\/doi.org\/10.1016\/j.reth.2021.06.002.","journal-title":"Regen Ther."},{"key":"3309_CR41","doi-asserted-by":"crossref","unstructured":"Binkley JM, Stratford PW, Lott SA, Riddle DL. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. Phys Ther. 1999;79(4):371\u201383.","DOI":"10.1037\/t35109-000"},{"issue":"5","key":"3309_CR42","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/jbmr.3377","volume":"33","author":"MP Whyte","year":"2018","unstructured":"Whyte MP, Fujita KP, Moseley S, Thompson DD, McAlister WH. Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the Radiographic Global Impression of Change scale. J Bone Miner Res. 2018;33(5):868\u201374. https:\/\/doi.org\/10.1002\/jbmr.3377.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"3309_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","volume":"46","author":"TD Thacher","year":"2000","unstructured":"Thacher TD, Fischer PR, Pettifor JM, et al. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000;46(3):132\u20139. https:\/\/doi.org\/10.1093\/tropej\/46.3.132.","journal-title":"J Trop Pediatr"},{"issue":"1","key":"3309_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"American Thoracic Society","year":"2002","unstructured":"American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137. https:\/\/doi.org\/10.1164\/ajrccm.166.1.at1102.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3309_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10131","volume":"3","author":"D Phillips","year":"2019","unstructured":"Phillips D, Tomazos IC, Moseley S, et al. Reliability and validity of the 6-minute walk test in hypophosphatasia. JBMR Plus. 2019;3(6): e10131. https:\/\/doi.org\/10.1002\/jbm4.10131.","journal-title":"JBMR Plus."},{"key":"3309_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","volume":"159","author":"EE Bleck","year":"1981","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111\u201322.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"3309_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1067\/mpd.2000.107892","volume":"137","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ. Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000;137(3):397\u2013402. https:\/\/doi.org\/10.1067\/mpd.2000.107892.","journal-title":"J Pediatr"},{"issue":"5","key":"3309_CR48","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s12325-025-03168-w","volume":"42","author":"KE Moss","year":"2025","unstructured":"Moss KE, Keen R, Fang S, et al. Mobility and quality of life in adults with paediatric-onset hypophosphatasia treated with asfotase alfa: results from UK Managed Access Agreement. Adv Ther. 2025;42(5):2429\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03168-w.","journal-title":"Adv Ther"},{"issue":"2","key":"3309_CR49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S. The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142\u20138. https:\/\/doi.org\/10.1111\/j.1532-5415.1991.tb01616.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"3309_CR50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0898264313475813","volume":"25","author":"F Zhang","year":"2013","unstructured":"Zhang F, Ferrucci L, Culham E, et al. Performance on five times sit-to-stand task as a predictor of subsequent falls and disability in older persons. J Aging Health. 2013;25(3):478\u201392. https:\/\/doi.org\/10.1177\/0898264313475813.","journal-title":"J Aging Health"},{"issue":"7","key":"3309_CR51","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.apmr.2017.10.006","volume":"99","author":"GE Hicks","year":"2018","unstructured":"Hicks GE, Sions JM, Velasco TO. Hip symptoms, physical performance, and health status in older adults with chronic low back pain: a preliminary investigation. Arch Phys Med Rehabil. 2018;99(7):1273\u20138. https:\/\/doi.org\/10.1016\/j.apmr.2017.10.006.","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"3309_CR52","doi-asserted-by":"publisher","first-page":"M85","DOI":"10.1093\/geronj\/49.2.m85","volume":"49","author":"JM Guralnik","year":"1994","unstructured":"Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85\u201394. https:\/\/doi.org\/10.1093\/geronj\/49.2.m85.","journal-title":"J Gerontol"},{"key":"3309_CR53","doi-asserted-by":"crossref","unstructured":"Bayley N. Bayley Scales of Infant and Toddler Development. Administration Manual. San Antonio, TX: Pearson, 2006.","DOI":"10.1037\/t14978-000"},{"key":"3309_CR54","unstructured":"Bruininks RH, Bruininks BD. BOT-2 Bruininks-Oseretsky Test of Motor Proficiency, Second Edition Complete Form Sample Report. Pearson Education, Inc., 2013. Available at: https:\/\/www.pearsonassessments.com\/content\/dam\/school\/global\/clinical\/us\/assets\/bot-2\/bot-2-complete-form-sample-report.pdf. Accessed May 11, 2016]."},{"key":"3309_CR55","volume-title":"Peabody Developmental Motor Scales","author":"MR Folio","year":"2000","unstructured":"Folio MR, Fewell RR. Peabody Developmental Motor Scales. Austin, TX: Pro-Ed Inc.; 2000."},{"issue":"4","key":"3309_CR56","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3109\/01942638.2011.572148","volume":"31","author":"HL Cintas","year":"2011","unstructured":"Cintas HL, Parks R, Don S, Gerber L. Brief assessment of motor function: content validity and reliability of the upper extremity gross motor scale. Phys Occup Ther Pediatr. 2011;31(4):440\u201350. https:\/\/doi.org\/10.3109\/01942638.2011.572148.","journal-title":"Phys Occup Ther Pediatr"},{"key":"3309_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20. https:\/\/doi.org\/10.1186\/1477-7525-1-20.","journal-title":"Health Qual Life Outcomes"},{"key":"3309_CR58","doi-asserted-by":"publisher","unstructured":"Daltroy LH, Liang MH, Fossel AH, Goldberg MJ. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. J Pediatr Orthop. 1998;18(5):561\u201371. https:\/\/doi.org\/10.1097\/00004694-199809000-00001.","DOI":"10.1097\/00004694-199809000-00001"},{"key":"3309_CR59","unstructured":"Cleeland CS. The Brief Pain Inventory User Guide. Houston, TX: The University of Texas M. D. Anderson Cancer Center, 2009. https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/BPI_UserGuide.pdf. Accessed May 22, 2025."},{"key":"3309_CR60","doi-asserted-by":"publisher","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312. https:\/\/doi.org\/10.1097\/00005650-200108000-00006.","DOI":"10.1097\/00005650-200108000-00006"},{"key":"3309_CR61","doi-asserted-by":"crossref","unstructured":"Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"3309_CR62","doi-asserted-by":"publisher","unstructured":"Ware JE, Jr. SF-36 Health Survey update. Spine (Phila Pa 1986). 2000;25(24):3130\u20139. https:\/\/doi.org\/10.1097\/00007632-200012150-00008.","DOI":"10.1097\/00007632-200012150-00008"},{"key":"3309_CR63","unstructured":"Van Reenen M, Oppe M. EQ-5D-3L User Guide. Rotterdam, The Netherlands: EuroQol Research Foundation, 2015. Available at: https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-3LUserguide-23-07.pdf. Accessed: May 22, 2025."},{"issue":"9","key":"3309_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85971","volume":"1","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Madson KL, Phillips D, et al. Asfotase alfa therapy for children with hypophosphatasia [with On-line Only Supplement]. JCI Insight. 2016;1(9): e85971. https:\/\/doi.org\/10.1172\/jci.insight.85971.","journal-title":"JCI Insight."},{"issue":"1","key":"3309_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cen.13343","volume":"87","author":"T Kitaoka","year":"2017","unstructured":"Kitaoka T, Tajima T, Nagasaki K, et al. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial. Clin Endocrinol (Oxf). 2017;87(1):10\u20139. https:\/\/doi.org\/10.1111\/cen.13343.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1\u20132","key":"3309_CR66","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymgme.2018.07.006","volume":"125","author":"T Akiyama","year":"2018","unstructured":"Akiyama T, Kubota T, Ozono K, et al. Pyridoxal 5\u2019-phosphate and related metabolites in hypophosphatasia: effects of enzyme replacement therapy. Mol Genet Metab. 2018;125(1\u20132):174\u201380. https:\/\/doi.org\/10.1016\/j.ymgme.2018.07.006.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3309_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial [with Supplementary Appendix]. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(18)30307-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3309_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362. https:\/\/doi.org\/10.1016\/j.bone.2018.12.011.","journal-title":"Bone"},{"issue":"7","key":"3309_CR69","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, Harmatz P, Vockley J, et al. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(7):2735\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02335.","journal-title":"J Clin Endocrinol Metab"},{"key":"3309_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115664","volume":"142","author":"L Seefried","year":"2021","unstructured":"Seefried L, Kishnani PS, Moseley S, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 2021;142: 115664. https:\/\/doi.org\/10.1016\/j.bone.2020.115664.","journal-title":"Bone"},{"issue":"9","key":"3309_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10395","volume":"4","author":"F Genest","year":"2020","unstructured":"Genest F, Rak D, Petryk A, Seefried L. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9): e10395. https:\/\/doi.org\/10.1002\/jbm4.10395.","journal-title":"JBMR Plus."},{"key":"3309_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116089","volume":"152","author":"RJ Schroth","year":"2021","unstructured":"Schroth RJ, Long C, Lee VHK, Alai-Towfigh H, Rockman-Greenberg C. Dental outcomes for children receiving asfotase alfa for hypophosphatasia. Bone. 2021;152: 116089. https:\/\/doi.org\/10.1016\/j.bone.2021.116089.","journal-title":"Bone"},{"key":"3309_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116856","volume":"175","author":"L Seefried","year":"2023","unstructured":"Seefried L, Genest F, Petryk A, Veith M. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment. Bone. 2023;175: 116856. https:\/\/doi.org\/10.1016\/j.bone.2023.116856.","journal-title":"Bone"},{"key":"3309_CR74","unstructured":"Kishnani P, Martos-Moreno G, Linglart A, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosophatasia: results from a global registry [abstract OC2; oral presentation]. Presented at: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; May 4\u20137, 2023; Barcelona, Spain."},{"key":"3309_CR75","doi-asserted-by":"publisher","unstructured":"Dahir KM, Ing SW, Deal C, et al. Improvement in quality of life after asfotase alfa treatment in adults with pediatric-onset hypophosphatasia: data from 5 patient-reported outcome measures. JBMR Plus. 2024;8(8):ziae062. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae062.","DOI":"10.1093\/jbmrpl\/ziae062"},{"key":"3309_CR76","doi-asserted-by":"publisher","unstructured":"Padidela R, Bishop N, Arundel P, et al. Mobility and quality of life in children with paediatric-onset hypophosphatasia treated with asfotase alfa: results from UK Managed Access Agreement. Adv Ther. 2025; in press. https:\/\/doi.org\/10.1007\/s12325-025-03225-4.","DOI":"10.1007\/s12325-025-03225-4"},{"issue":"5","key":"3309_CR77","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/15513818809022304","volume":"8","author":"MM Silver","year":"1988","unstructured":"Silver MM, Vilos GA, Milne KJ. Pulmonary hypoplasia in neonatal hypophosphatasia. Pediatr Pathol. 1988;8(5):483\u201393. https:\/\/doi.org\/10.3109\/15513818809022304.","journal-title":"Pediatr Pathol"},{"key":"3309_CR78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2021.12.009","volume":"130","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Shimura K, Yoshihashi H, Miyama S. Status epilepticus due to asfotase alfa interruption in perinatal severe hypophosphatasia. Pediatr Neurol. 2022;130:4\u20136. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.12.009.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"3309_CR79","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jbm4.10052","volume":"2","author":"P Klidaras","year":"2018","unstructured":"Klidaras P, Severt J, Aggers D, et al. Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus. 2018;2(5):304\u20137. https:\/\/doi.org\/10.1002\/jbm4.10052.","journal-title":"JBMR Plus."},{"key":"3309_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115794","volume":"143","author":"J St\u00fcrznickel","year":"2021","unstructured":"St\u00fcrznickel J, Schmidt FN, von Vopelius E, et al. Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia. Bone. 2021;143: 115794. https:\/\/doi.org\/10.1016\/j.bone.2020.115794.","journal-title":"Bone"},{"issue":"11","key":"3309_CR81","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.4130","volume":"35","author":"L Seefried","year":"2020","unstructured":"Seefried L, Dahir K, Petryk A, et al. Burden of illness in adults with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry. J Bone Miner Res. 2020;35(11):2171\u20138. https:\/\/doi.org\/10.1002\/jbmr.4130.","journal-title":"J Bone Miner Res"},{"key":"3309_CR82","unstructured":"Seefried L, Dahir K, Martos-Moreno G, et al. Fracture rate and location in adults with hypophosphatasia with one versus multiple ALPL variants: data from the Global HPP Registry [abstract OC35]. Aging Clin Exp Res. 2024;36(Suppl 1):24."},{"issue":"1","key":"3309_CR83","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13023-022-02230-y","volume":"17","author":"Y Sugiyama","year":"2022","unstructured":"Sugiyama Y, Watanabe T, Tajika M, et al. A Japanese single-center experience of the efficacy and safety of asfotase alfa in pediatric-onset hypophosphatasia. Orphanet J Rare Dis. 2022;17(1):78. https:\/\/doi.org\/10.1186\/s13023-022-02230-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3309_CR84","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/ccr3.2769","volume":"8","author":"L Kiselnikova","year":"2020","unstructured":"Kiselnikova L, Vislobokova E, Voinova V. Dental manifestations of hypophosphatasia in children and the effects of enzyme replacement therapy on dental status: a series of clinical cases. Clin Case Rep. 2020;8(5):911\u20138. https:\/\/doi.org\/10.1002\/ccr3.2769.","journal-title":"Clin Case Rep."},{"issue":"1","key":"3309_CR85","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","volume":"19","author":"PS Kishnani","year":"2024","unstructured":"Kishnani PS, Martos-Moreno G, Linglart A, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024;19(1):109. https:\/\/doi.org\/10.1186\/s13023-024-03048-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3309_CR86","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/biom10030432","volume":"10","author":"M Herrmann","year":"2020","unstructured":"Herrmann M, Engelke K, Ebert R, et al. Interactions between muscle and bone-where physics meets biology. Biomolecules. 2020;10(3):432. https:\/\/doi.org\/10.3390\/biom10030432.","journal-title":"Biomolecules"},{"issue":"7960","key":"3309_CR87","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0140-6736(76)90428-1","volume":"1","author":"GD Schott","year":"1976","unstructured":"Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet. 1976;1(7960):626\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(76)90428-1.","journal-title":"Lancet"},{"issue":"10","key":"3309_CR88","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1096\/fj.202000767R","volume":"34","author":"P Marchetti","year":"2020","unstructured":"Marchetti P, Fovez Q, Germain N, Khamari R, Kluza J. Mitochondrial spare respiratory capacity: mechanisms, regulation, and significance in non-transformed and cancer cells. FASEB J. 2020;34(10):13106\u201324. https:\/\/doi.org\/10.1096\/fj.202000767R.","journal-title":"FASEB J"},{"issue":"21","key":"3309_CR89","doi-asserted-by":"publisher","first-page":"15905","DOI":"10.3390\/ijms242115905","volume":"24","author":"EG Pendleton","year":"2023","unstructured":"Pendleton EG, Nichenko AS, McFaline-Figueroa J, et al. Compromised muscle properties in a severe hypophosphatasia murine model. Int J Mol Sci. 2023;24(21):15905. https:\/\/doi.org\/10.3390\/ijms242115905.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3309_CR90","doi-asserted-by":"publisher","first-page":"16945","DOI":"10.1038\/s41598-018-35079-y","volume":"8","author":"DK Williams","year":"2018","unstructured":"Williams DK, Pinz\u00f3n C, Huggins S, et al. Genetic engineering a large animal model of human hypophosphatasia in sheep. Sci Rep. 2018;8(1):16945. https:\/\/doi.org\/10.1038\/s41598-018-35079-y.","journal-title":"Sci Rep"},{"key":"3309_CR91","unstructured":"Bertels J, Falck A, Huggins S, et al. Impaired mitochondrial respiration and altered fiber type in hypophosphatasia sheep skeletal muscle [poster]. Presented at: Annual Meeting of the American Society for Bone and Mineral Research; September 11\u201315, 2020."},{"key":"3309_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104915","volume":"68","author":"Z Zervou","year":"2024","unstructured":"Zervou Z, Plooij R, van Velsen EFS, et al. Impressive clinical improvement and disappearance of neuropathic pain in an adult patient with hypophosphatasia treated with asfotase alfa. Eur J Med Genet. 2024;68: 104915. https:\/\/doi.org\/10.1016\/j.ejmg.2024.104915.","journal-title":"Eur J Med Genet"},{"key":"3309_CR93","unstructured":"Linglart A, Dahir KM, Kishnani P, et al. Frequency of ectopic calcifications among patients with hypophosphatasia in the Global HPP Registry. Presented at: ENDO 2021, the 103rd Annual Meeting and Expo of the Endocrine Society; March 20\u201323, 2021."},{"issue":"8","key":"3309_CR94","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1210\/jc.2018-02413","volume":"104","author":"C Rockman-Greenberg","year":"2019","unstructured":"Rockman-Greenberg C. Letter to the editor: efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(8):3146\u20137. https:\/\/doi.org\/10.1210\/jc.2018-02413.","journal-title":"J Clin Endocrinol Metab"},{"key":"3309_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101617","volume":"17","author":"C Rockman-Greenberg","year":"2022","unstructured":"Rockman-Greenberg C, Josse R, Francis M, Mhanni A. Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: a case series. Bone Rep. 2022;17: 101617. https:\/\/doi.org\/10.1016\/j.bonr.2022.101617.","journal-title":"Bone Rep."},{"issue":"3","key":"3309_CR96","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00198-023-06859-8","volume":"35","author":"ML Brandi","year":"2024","unstructured":"Brandi ML, Khan AA, Rush ET, et al. The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance. Osteoporosis Int. 2024;35(3):439\u201349. https:\/\/doi.org\/10.1007\/s00198-023-06859-8.","journal-title":"Osteoporosis Int"},{"issue":"1","key":"3309_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00223-025-01371-z","volume":"116","author":"L Seefried","year":"2025","unstructured":"Seefried L, Rak D, Genest F. Grading pseudofractures\u2014The \u201cBreach \u2013 Beak \u2013 Bump \u2013 Bridge\u201d approach. Calcif Tissue Int. 2025;116(1):62. https:\/\/doi.org\/10.1007\/s00223-025-01371-z.","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"3309_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10713","volume":"7","author":"R Zebaze","year":"2023","unstructured":"Zebaze R, Shore-Lorenti C, Nguyen HH, et al. A quantification method for disorganized bone components: application to the femoral shaft. JBMR Plus. 2023;7(2): e10713. https:\/\/doi.org\/10.1002\/jbm4.10713.","journal-title":"JBMR Plus."},{"key":"3309_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115413","volume":"137","author":"JH Simmons","year":"2020","unstructured":"Simmons JH, Rush ET, Petryk A, Zhou S, Martos-Moreno G. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: a pooled post hoc analysis of asfotase alfa clinical trial data. Bone. 2020;137: 115413. https:\/\/doi.org\/10.1016\/j.bone.2020.115413.","journal-title":"Bone"},{"issue":"3","key":"3309_CR100","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/tomography7030034","volume":"7","author":"G Foti","year":"2021","unstructured":"Foti G, Serra G, Iacono V, et al. Identification of non-traumatic bone marrow oedema: the pearls and pitfalls of dual-energy CT (DECT). Tomography (Ann Arbor, Mich). 2021;7(3):387\u201396. https:\/\/doi.org\/10.3390\/tomography7030034.","journal-title":"Tomography (Ann Arbor, Mich)."},{"issue":"2","key":"3309_CR101","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/02701367.1999.10608028","volume":"70","author":"CJ Jones","year":"1999","unstructured":"Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999;70(2):113\u20139. https:\/\/doi.org\/10.1080\/02701367.1999.10608028.","journal-title":"Res Q Exerc Sport"},{"issue":"4","key":"3309_CR102","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/0898264314525665","volume":"26","author":"A Yazdanyar","year":"2014","unstructured":"Yazdanyar A, Aziz MM, Enright PL, et al. Association between 6-Minute Walk Test and all-cause mortality, coronary heart disease-specific mortality, and incident coronary heart disease. J Aging Health. 2014;26(4):583\u201399. https:\/\/doi.org\/10.1177\/0898264314525665.","journal-title":"J Aging Health"},{"issue":"3","key":"3309_CR103","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/PRM-170523","volume":"11","author":"D Phillips","year":"2018","unstructured":"Phillips D, Griffin D, Przybylski T, et al. Development and validation of a modified performance-oriented mobility assessment tool for assessing mobility in children with hypophosphatasia. J Pediatr Rehabil Med. 2018;11(3):187\u201392. https:\/\/doi.org\/10.3233\/PRM-170523.","journal-title":"J Pediatr Rehabil Med."},{"issue":"3","key":"3309_CR104","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1086\/511788","volume":"80","author":"JA Mayr","year":"2007","unstructured":"Mayr JA, Merkel O, Kohlwein SD, et al. Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation. Am J Hum Genet. 2007;80(3):478\u201384. https:\/\/doi.org\/10.1086\/511788.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"3309_CR105","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1021\/acscatal.9b03907","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Zhao Y, Zhou H, Luo HB, Zhan CG. Catalytic roles of coenzyme pyridoxal-5\u2019-phosphate (PLP) in PLP-dependent enzymes: reaction pathway for methionine-\u03b3-lyase-catalyzed L-methionine depletion. ACS Catal. 2020;10(3):2198\u2013210. https:\/\/doi.org\/10.1021\/acscatal.9b03907.","journal-title":"ACS Catal"},{"issue":"10","key":"3309_CR106","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/jbmr\/zjae128","volume":"39","author":"KM Dahir","year":"2024","unstructured":"Dahir KM, Shannon A, Dunn D, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024;39(10):1412\u201323. https:\/\/doi.org\/10.1093\/jbmr\/zjae128.","journal-title":"J Bone Miner Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03309-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03309-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:29:28Z","timestamp":1764311368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03309-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03309-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aliya A. Khan has received honoraria from Amgen and Alexion and support from Ascendis, Calcilytix, Amolyt, and Alexion, AstraZeneca Rare Disease. Eric T. Rush has received consulting fees, support for attending meetings, and honoraria from Alexion, AstraZeneca Rare Disease. He is also on the Alexion advisory board and his institution has received grants from Alexion, AstraZeneca Rare Disease. Craig Wakeford and Daniel Staub are employees of and may own stock\/options in Alexion, AstraZeneca Rare Disease. Maria Luisa Brandi has received consulting fees, support for attending meetings, and honoraria from Alexion, AstraZeneca Rare Disease. She is also on the Alexion advisory board and her institution has received grants from Alexion, AstraZeneca Rare Disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review article did not require institutional review board or institutional animal care and use committee approval, as it is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}